News
Articles
Updated indication criteria for genetic testing of hereditary cancer syndromes
On 9 October 2024, the Committee of the Society of Medical Genetics and Genomics of the Czech Medical Society J.E.Purkyně approved the updated extended indication criteria for germline genetic testing for the most common adult cancers. The list of criteria can be found in the download section of our website and in the appendix of this report.
We offer a new examination "Pharmacogenetics of statins"
Statins inhibit the internal production of cholesterol in the liver, leading to a reduction in total and LDL-cholesterol levels in the blood. However, in a proportion of the population, they cause muscular side effects, particularly myopathy, which can lead to the development of rhabdomyolysis. The more common manifestation of myopathy in the form of muscle pain, weakness or fatigue is a common reason why patients stop taking the medication.
We actively participated in the "veptc 2024" course in Palermo, Sicily
Colleagues from GHC Genetics laboratory actively participated in the important "Variant effect prediction training course", which took place on 13-16.10.2024 in Palermo, Sicily. The event was organized by the Human Genome Organization (HUGO) and focused on predicting the effects of genomic variants found in patients using sequencing. This course focuses on helping participants to effectively analyse and interpret DNA variants, a crucial task for those involved in genomic diagnostics, such as molecular geneticists, clinical geneticists and laboratory professionals.
Article by Dr. Tereza Piskáčková on genetic predisposition to prostate cancer
Tereza Piskáčková, M.D., published an article "Hereditary predisposition for prostate cancer" in the latest issue of the periodical Acta Medicinae. The full article can be downloaded in the appendix of this article.